{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NK+Cell", "query": { "condition": "NK Cell" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 451, "total_pages": 46, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NK+Cell&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-21T23:46:09.763Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03420963", "title": "Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Cutaneous Melanoma", "Recurrent Lip and Oral Cavity Carcinoma", "Recurrent Malignant Endocrine Neoplasm", "Recurrent Malignant Female Reproductive System Neoplasm", "Recurrent Malignant Male Reproductive System Neoplasm", "Recurrent Malignant Mesothelioma", "Recurrent Malignant Neoplasm of Multiple Primary Sites", "Recurrent Malignant Oral Neoplasm", "Recurrent Malignant Pharyngeal Neoplasm", "Recurrent Malignant Skin Neoplasm", "Recurrent Malignant Soft Tissue Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Thyroid Gland Neoplasm", "Recurrent Malignant Urinary System Neoplasm", "Refractory Cutaneous Melanoma", "Refractory Malignant Bone Neoplasm", "Refractory Malignant Endocrine Neoplasm", "Refractory Malignant Female Reproductive System Neoplasm", "Refractory Malignant Male Reproductive System Neoplasm", "Refractory Malignant Mesothelioma", "Refractory Malignant Neoplasm of Multiple Primary Sites", "Refractory Malignant Oral Neoplasm", "Refractory Malignant Pharyngeal Neoplasm", "Refractory Malignant Skin Neoplasm", "Refractory Malignant Soft Tissue Neoplasm", "Refractory Malignant Solid Neoplasm", "Refractory Malignant Thyroid Gland Neoplasm", "Refractory Malignant Urinary System Neoplasm" ], "interventions": [ { "name": "Cord Blood-derived Expanded Allogeneic Natural Killer Cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Months to 40 Years" }, "enrollment_count": 12, "start_date": "2018-08-31", "completion_date": "2026-02-26", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-07-21T23:46:09.763Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03420963" }, { "nct_id": "NCT00720785", "title": "Natural Killer Cells and Bortezomib to Treat Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloid Leukemia (CML)", "Pancreatic Ca", "Colon/Rectal Ca", "Multiple Myeloma", "Carcinoma, Non-Small -Cell Lung" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "NK cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 35, "start_date": "2008-08-01", "completion_date": "2021-04-06", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-21T23:46:09.763Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720785" }, { "nct_id": "NCT05447078", "title": "Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Immulina TM", "type": "DRUG" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "University of Mississippi Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 492, "start_date": "2022-07-01", "completion_date": "2025-12-08", "has_results": false, "last_update_posted_date": "2025-12-26", "last_synced_at": "2026-07-21T23:46:09.763Z", "location_count": 1, "location_summary": "Jackson, Mississippi", "locations": [ { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT05447078" }, { "nct_id": "NCT00145626", "title": "HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Myelodysplasia", "Chronic Myeloid Leukemia", "Histiocytosis" ], "interventions": [ { "name": "Chemotherapy and antibodies", "type": "DRUG" }, { "name": "Miltenyi Biotec CliniMACS", "type": "DEVICE" }, { "name": "Allogeneic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "24 Months", "sex": "ALL", "summary": "Up to 24 Months" }, "enrollment_count": 40, "start_date": "2004-05", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2017-06-19", "last_synced_at": "2026-07-21T23:46:09.763Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00145626" }, { "nct_id": "NCT06991114", "title": "AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Rheumatoid Arthritis (RA)", "Idiopathic Inflammatory Myopathies (IIMs)", "Systemic Sclerosis (SSc)", "Rheumatoid Arthritis (RA", "IIM", "Myositis", "Scleroderma", "Sjogren Syndrome", "Sjogrens Disease" ], "interventions": [ { "name": "Allogeneic NK Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artiva Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-07-09", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-07-21T23:46:09.763Z", "location_count": 31, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06991114" }, { "nct_id": "NCT05883449", "title": "Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Hodgkin Lymphoma", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "AFM13", "type": "DRUG" }, { "name": "AB-101", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affimed GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-10-10", "completion_date": "2025-06-13", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-07-21T23:46:09.763Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05883449" }, { "nct_id": "NCT01652014", "title": "Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "double-unit umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2014-01", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-07-21T23:46:09.763Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01652014" }, { "nct_id": "NCT07579208", "title": "A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Phase 1", "NK Cell", "IL13Ra", "EGFRvIII", "Chimera Antigen Receptor (CAR)", "NR3C1", "Recurrent Glioblastoma" ], "interventions": [ { "name": "NK Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-10-24", "completion_date": "2030-07-30", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-07-21T23:46:09.763Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07579208" }, { "nct_id": "NCT00586703", "title": "Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "NK-CD56", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "David Rizzieri, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2005-04", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2014-06-12", "last_synced_at": "2026-07-21T23:46:09.763Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00586703" }, { "nct_id": "NCT06066359", "title": "Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Myeloma" ], "interventions": [ { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 44, "start_date": "2023-11-30", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-07-21T23:46:09.763Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06066359" } ] }